Bristol-Myers Squibb (BMY) Receives Positive EMA Opinion for Opdivo as Advanced Melanoma Treatment
The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Opdivo (nivolumab). Opdivo is recommended to be used ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)